UK Government Selects Pfizer Over GSK to Supply RSV Vaccine Doses

1. UK Government's Decision: The UK government has chosen Pfizer to supply millions of respiratory syncytial virus (RSV) vaccine doses, favoring it over local pharmaceutical company GlaxoSmithKline (GSK) and its competing product.
2. Contract Details: Pfizer will provide over 35 million doses of its Abrys vaccine to older adults and more than 4 million doses to pregnant mothers in England and Northern Ireland over the next two years.
3. Impact on GSK: This decision marks a significant setback for GSK, a British pharmaceutical company, which had been competing for the contract.
4. RSV Vaccine Importance: The RSV vaccine is crucial for protecting against respiratory syncytial virus, which can cause severe respiratory illness, particularly in older adults and young children.
5. Industry Implications: This decision highlights the competitive landscape in the pharmaceutical industry, where global companies like Pfizer are gaining ground over local players like GSK.